TriangleNCT00565851 · OUTCOME
Patient Reported Physical Function (Chemotherapy Analysis)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- LEAST_SQUARES_MEAN
- Unit
- score on a scale
- Interval / dispersion
- Standard Error
- Time frame
- 1. Prior to cycle 1 (baseline), 2. Prior to cycle 3 (6 weeks post cycle 1), 3. Prior to cycle 6 (15 weeks post cycle 1), 4. 6 months post cycle 1, 5. 12 months post cycle 1.
What was measured
Patient reported physical functioning was measured with physical functioning subscale of the RAND SF-36. The Physical Functioning Subscale consists of 10 items concerning activities of daily living: walking, climbing stairs, bathing, dressing, and performance of physical activities. Each item is rated on a three-point scale of limitation of activity due to the patients' health from 1=limited a lot to 3=not limited. The total PF score is the summation of item scores and then rescaled to 0-100. A larger score suggests better physical functioning.
Analysis population: Provided baseline and at least one follow-up assessments (data were combined and analyzed according to randomized chemotherapy regimen, regardless of surgical assignment, as pre-specified in the study protocol).
Groups in this outcome
Paclitaxel and Carboplatin Chemotherapy
All patients who received paclitaxel and carboplatin chemotherapy and were included in the chemotherapy analysis
Paclitaxel and Carboplatin Chemotherapy With Bevacizumab
All patients who received paclitaxel and carboplatin chemotherapy with bevacizumab followed by bevacizumab maintenance therapy and were included in the chemotherapy analysis
| Group | Source count |
|---|---|
| Paclitaxel and Carboplatin Chemotherapy | 298 |
| Paclitaxel and Carboplatin Chemotherapy With Bevacizumab | 302 |
Reported measurements
Prior to cycle 1 (baseline)
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Paclitaxel and Carboplatin Chemotherapy | 71.5 | 1.6 | Not reported | Not reported | Not reported |
| Paclitaxel and Carboplatin Chemotherapy With Bevacizumab | 69.4 | 1.7 | Not reported | Not reported | Not reported |
Prior to cycle 3
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Paclitaxel and Carboplatin Chemotherapy | 73.2 | 2.1 | Not reported | Not reported | Not reported |
| Paclitaxel and Carboplatin Chemotherapy With Bevacizumab | 69.8 | 2.1 | Not reported | Not reported | Not reported |
Prior to cycle 6
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Paclitaxel and Carboplatin Chemotherapy | 71.5 | 2.2 | Not reported | Not reported | Not reported |
| Paclitaxel and Carboplatin Chemotherapy With Bevacizumab | 64.6 | 2.2 | Not reported | Not reported | Not reported |
6 months post cycle 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Paclitaxel and Carboplatin Chemotherapy | 71.6 | 2.2 | Not reported | Not reported | Not reported |
| Paclitaxel and Carboplatin Chemotherapy With Bevacizumab | 70.2 | 2.1 | Not reported | Not reported | Not reported |
12 months post cycle 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Paclitaxel and Carboplatin Chemotherapy | 71.8 | 2.2 | Not reported | Not reported | Not reported |
| Paclitaxel and Carboplatin Chemotherapy With Bevacizumab | 70.7 | 2.2 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 1.6
- value
- 71.5
- group Id
- OG001
- spread
- 1.7
- value
- 69.4
- title
- Prior to cycle 1 (baseline)
- categories
- measurements
- group Id
- OG000
- spread
- 2.1
- value
- 73.2
- group Id
- OG001
- spread
- 2.1
- value
- 69.8
- title
- Prior to cycle 3
- categories
- measurements
- group Id
- OG000
- spread
- 2.2
- value
- 71.5
- group Id
- OG001
- spread
- 2.2
- value
- 64.6
- title
- Prior to cycle 6
- categories
- measurements
- group Id
- OG000
- spread
- 2.2
- value
- 71.6
- group Id
- OG001
- spread
- 2.1
- value
- 70.2
- title
- 6 months post cycle 1
- categories
- measurements
- group Id
- OG000
- spread
- 2.2
- value
- 71.8
- group Id
- OG001
- spread
- 2.2
- value
- 70.7
- title
- 12 months post cycle 1
- denoms
- counts
- group Id
- OG000
- value
- 298
- group Id
- OG001
- value
- 302
- units
- Participants
- description
- Patient reported physical functioning was measured with physical functioning subscale of the RAND SF-36. The Physical Functioning Subscale consists of 10 items concerning activities of daily living: walking, climbing stairs, bathing, dressing, and performance of physical activities. Each item is rated on a three-point scale of limitation of activity due to the patients' health from 1=limited a lot to 3=not limited. The total PF score is the summation of item scores and then rescaled to 0-100. A larger score suggests better physical functioning.
- dispersion Type
- Standard Error
- groups
- description
- All patients who received paclitaxel and carboplatin chemotherapy and were included in the chemotherapy analysis
- id
- OG000
- title
- Paclitaxel and Carboplatin Chemotherapy
- description
- All patients who received paclitaxel and carboplatin chemotherapy with bevacizumab followed by bevacizumab maintenance therapy and were included in the chemotherapy analysis
- id
- OG001
- title
- Paclitaxel and Carboplatin Chemotherapy With Bevacizumab
- param Type
- LEAST_SQUARES_MEAN
- population Description
- Provided baseline and at least one follow-up assessments (data were combined and analyzed according to randomized chemotherapy regimen, regardless of surgical assignment, as pre-specified in the study protocol).
- reporting Status
- POSTED
- time Frame
- 1. Prior to cycle 1 (baseline), 2. Prior to cycle 3 (6 weeks post cycle 1), 3. Prior to cycle 6 (15 weeks post cycle 1), 4. 6 months post cycle 1, 5. 12 months post cycle 1.
- title
- Patient Reported Physical Function (Chemotherapy Analysis)
- type
- SECONDARY
- unit Of Measure
- score on a scale
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice